Keymed Biosciences (HKSE:02162) Change In Payables And Accrued Expense : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Change In Payables And Accrued Expense?

Keymed Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was HK$0.0 Mil. It means Keymed Biosciences's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Keymed Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was HK$0.0 Mil. It means Keymed Biosciences's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Keymed Biosciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Keymed Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Change In Payables And Accrued Expense Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial				-	-	-	-	-

Keymed Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Keymed Biosciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines